NAACCR Item #3869: LDH Pretreatment Level
Padding Character' '
|Item #||Length||Source of Standard||Year Implemented||Version Implemented||Year Retired||Version Retired||Column #|
|3869||1||NAACCR||2018||18||1916 - 1916|
NAACCR XML: Tumor.ldhPretreatmentLevel
LDH (Lactate Dehydrogenase) is an enzyme involved in conversion of sugars to energy and present in most cells in the body. Elevated pretreatment LDH is an adverse prognostic factor for plasma cell myeloma and melanoma of the skin.
LDH (Lactate Dehydrogenase) Pretreatment Level is a prognostic factor required in AJCC 8th edition for Chapter 83 Plasma Cell Myeloma and Plasma Cell Disorders and Chapter 47 Melanoma Skin. For Plasma Cell Myeloma, LDH is part of the RISS Stage and is new for cases diagnosed 1/1/2018+. For Melanoma Skin, LDH is used to define the M subcategories and was previously collected as Melanoma Skin, SSF #4.
|0||Normal LDH level
Low, below normal
|1||Above normal LDH level; High|
|7||Test ordered, results not in chart|
|9||Not documented in medical record
LDH (Lactate Dehydrogenase) Pretreatment Level not assessed or unknown if assessed
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.